<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">622874</article-id><article-id pub-id-type="doi">10.35693/SIM622874</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Oncology and radiotherapy</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Онкология, лучевая терапия</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Gender-specific aspects of oncological diseases: focus on stomach cancer and colorectal cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Половая специфика онкологических заболеваний: рак желудка и колоректальный рак</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5115-6388</contrib-id><name-alternatives><name xml:lang="en"><surname>Gataullin</surname><given-names>Ilgiz G.</given-names></name><name xml:lang="ru"><surname>Гатауллин</surname><given-names>Ильгиз Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Professor, Department of Oncology, Radiology and Palliative Medicine</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры онкологии, радиологии и паллиативной медицины</p></bio><email>ilgizg@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-8570-5904</contrib-id><name-alternatives><name xml:lang="en"><surname>Dinov</surname><given-names>Rishat M.</given-names></name><name xml:lang="ru"><surname>Динов</surname><given-names>Ришат М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>oncologist and a Resident of the Department of Oncology, Radiology and Palliative Medicine</p></bio><bio xml:lang="ru"><p>ординатор кафедры онкологии, радиологии и паллиативной медицины</p></bio><email>rishatdinov@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1695-168X</contrib-id><name-alternatives><name xml:lang="en"><surname>Gataullin</surname><given-names>Bulat I.</given-names></name><name xml:lang="ru"><surname>Гатауллин</surname><given-names>Булат И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Associate professor, Department of Surgery at the Institute of Fundamental Medicine and Biology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры хирургии Института фундаментальной медицины и биологии</p></bio><email>bulatg@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-0937-928X</contrib-id><name-alternatives><name xml:lang="en"><surname>Erpert</surname><given-names>Yana А.</given-names></name><name xml:lang="ru"><surname>Эрперт</surname><given-names>Яна А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>resident of the Department of Oncology, Radiology and Palliative Medicine</p></bio><bio xml:lang="ru"><p>ординатор кафедры онкологии, радиологии и паллиативной медицины</p></bio><email>yana.erpert@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical Academy</institution></aff><aff><institution xml:lang="ru">Казанская государственная медицинская академия – филиал ФГБОУ ДПО РМАНПО Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kazan (Volga region) Federal University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Казанский (Приволжский) федеральный университет»</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2024-02-06" publication-format="electronic"><day>06</day><month>02</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-06-03" publication-format="electronic"><day>03</day><month>06</month><year>2024</year></pub-date><volume>9</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>138</fpage><lpage>142</lpage><history><date date-type="received" iso-8601-date="2023-10-30"><day>30</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-01-19"><day>19</day><month>01</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Gataullin I.G., Dinov R.M., Gataullin B.I., Erpert Y.А.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Гатауллин И.Г., Динов Р.М., Гатауллин Б.И., Эрперт Я.А.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Gataullin I.G., Dinov R.M., Gataullin B.I., Erpert Y.А.</copyright-holder><copyright-holder xml:lang="ru">Гатауллин И.Г., Динов Р.М., Гатауллин Б.И., Эрперт Я.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/622874">https://innoscience.ru/2500-1388/article/view/622874</self-uri><abstract xml:lang="en"><p>With each passing day, medicine strives to become more personalized, centered directly on the patient. A significant aspect of this dynamic involves the consideration of patients' gender, which influences their physiology, the pathogenesis of developing diseases, and their response to treatment.</p> <p>Historically, most research has been conducted on male cells, male mice, and men, with women of childbearing age often excluded from studies for their safety. It was assumed that female cells were identical to male cells, leading medical research to be predominantly focused on male physiology. However, this approach was fundamentally flawed, as individuals of different sexes differ in terms of epidemiology, pathogenesis, clinical manifestations, disease progression, and responses to treatment. Knowledge of these gender-specific characteristics can aid clinicians in their patient management.</p> <p>This literature review aims to examine the peculiarities of cancer progression in men and women, specifically in the cases of stomach and colorectal cancer.</p></abstract><trans-abstract xml:lang="ru"><p>С каждым днем медицина стремится стать более персонализированной, ориентированной непосредственно на пациента. Немалая роль в этом направлении отводится половым особенностям человека, от которых зависит его физиология, патогенез развивающихся в нем заболеваний, а также его реакция на лечение.</p> <p>Исторически сложилось так, что большинство исследований проводятся на мужских клетках, самцах мышей и мужчинах. Женщин детородного возраста исключали из исследований для их безопасности, считая их клетки идентичными мужским, и в результате медицинские исследования были сосредоточены только на мужской физиологии. Однако данный подход был в корне неверным, поскольку представители разных полов отличаются по эпидемиологии, патогенезу, клиническим проявлениям и прогрессированию заболеваний, а также реакциям на оказываемое лечение. Знание данных особенностей может помочь врачу-клиницисту в ведении пациентов в своей практике.</p> <p>Литературный обзор нацелен на изучение особенностей течения у мужчин и женщин рака желудка и колоректального рака.</p></trans-abstract><kwd-group xml:lang="en"><kwd>sex</kwd><kwd>gender</kwd><kwd>stomach cancer</kwd><kwd>colorectal cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пол</kwd><kwd>гендер</kwd><kwd>рак желудка</kwd><kwd>колоректальный рак</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care for the population of Russia in 2022. M., 2022. (In Russ.). [Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2022 году. М., 2022].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Rubin JB. The spectrum of sex differences in cancer. Trends Cancer. 2022;8(4):303-315. https://doi.org/10.1016/j.trecan.2022.01.013</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>McCartney G, Mahmood L, Leyland AH, et al. Contribution of smoking-related and alcohol-related deaths to the gender gap in mortality: evidence from 30 European countries. Tob Control. 2011;20:166-68. https://doi.org/10.1136/tc.2010.037929</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16:330-39. https://doi.org/10.1038/nrc.2016.30</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Wagner AD, Oertelt-Prigione S, Adjei A, et al. Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019;30:1912-1924. https://doi.org/10.1093/annonc/mdz414</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Abolfazl A, Sara A, Seidamir PT, et al. Overview of epidemiological characteristics, clinical features, and risk factors of gastric cancer in Asia-Pacific region. Asia Pac J Clin Oncol. 2022;18(6):493-505. https://doi.org/10.1111/ajco.13654</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Deng W, Jin L, Zhuo H. Alcohol consumption and risk of stomach cancer: A meta-analysis. Chem Biol Interact. 2021;336:109365. https://doi.org/10.1016/j.cbi.2021.109365</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>DeVita VT, Lawrence TS, Rosenberg SA. Cancer: Principles and Practice of Oncology. 2015, 10th ed. Philadelphia, PA: Wolters Kluwer.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Waldum HL, Fossmark R. Types of Gastric Carcinomas. Int J Mol Sci. 2018;19(12):4109. https://doi.org/10.3390/ijms19124109</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Yao Q, Qi X, Xie SH. Sex difference in the incidence of cardia and non-cardia gastric cancer in the United States, 1992-2014. BMC Gastroenterol. 2020;20(1):418. https://doi.org/10.1186/s12876-020-01551-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ilic M, Ilic I. Epidemiology of stomach cancer. World J Gastroenterol. 2022;28(12):1187-1203. https://doi.org/10.3748/wjg.v28.i12.1187</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Colquhoun A, Arnold M, Ferlay J, et al. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881-1888. https://doi.org/10.1136/gutjnl-2014-308915</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397-2403. https://doi.org/10.1016/j.ejca.2008.07.031</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Derakhshan MH, Liptrot S, Paul J, et al. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16-23. https://doi.org/10.1136/gut.2008.161331</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rutegard M, Shore R, Lu Y, Lagergren P, et al. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970-2006. Eur J Cancer. 2010;46(6):1093-1100. https://doi.org/10.1016/j.ejca.2010.01.029</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Luan X, Niu P, Wang W, et al. Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. J Oncol. 2022:1269435. https://doi.org/10.1155/2022/1269435</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Hsu LW, Huang KH, Chen MH, et al. Genetic alterations in gastric cancer patients according to sex. Aging. 2020;13(1):376-388. https://doi.org/10.18632/aging.202142</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kohlruss M, Ott K, Grosser B, et al. Sexual difference matters: females with high microsatellite instability show increased survival after neoadjuvant chemotherapy in gastric cancer. Cancers. 2021;13(5):1048. https://doi.org/10.3390/cancers13051048</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Kalff MC, Wagner AD, Verhoeven RHA, et al. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer. 2022;25(1):22-32. https://doi.org/10.1007/s10120-021-01225-1</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lee SS, Ryu SW, Kim IH, Sohn SS. Impact of gender and body mass index on surgical outcomes following gastrectomy: an Asia-Pacific perspective. Chinese Medical Journal. 2012;125(1):67-71. PMID: 22340468</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Park HC, Shin A, Kim BW, et al. Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctol. 2013;29(4):144-149. https://doi.org/10.3393/ac.2013.29.4.144</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211-219. https://doi.org/10.1001/jamaoncol.2016.4227</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61(1):126-130. PMID: 11196149</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Quaas A, Biesma HD, Wagner AD, Verheij M, et al. Microsatellite instability and sex differences in resectable gastric cancer – A pooled analysis of three European cohorts. Eur J Cancer. 2022;173:95-104. https://doi.org/10.1016/j.ejca.2022.06.025</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis. 2013;28(12):1637-1642. https://doi.org/10.1007/s00384-013-1715-8</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Wiencke JK, Zheng S, Lafuente A, et al. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(6):501-506. PMID: 10385139</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Liao H, Li C, Ai Y, Kou Y. Gut microbiome is more stable in males than in females during the development of colorectal cancer. J Appl Microbiol. 2021;131(1):435-448. https://doi.org/10.1111/jam.14943</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Baraibar I, Ros J, Saoudi N, et al. Sex and gender perspectives in colorectal cancer. ESMO Open. 2023;8(2):101204. https://doi.org/10.1016/j.esmoop.2023.101204</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Prado CMM, Baracos V, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268. https://doi.org/10.1158/1078-0432.CCR-06-3067</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283. https://doi.org/10.1016/0006-2952(92)90010-g</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet. 2003;42:779-791. https://doi.org/10.2165/00003088-200342090-00001</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Micheli A, Ciampichini R, Oberaigner W, et al. EUROCARE Working Group. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017-27. https://doi.org/10.1016/j.ejca.2008.11.008</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21(10):2023-2028. https://doi.org/10.1093/annonc/mdq067</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Cristina V, Mahachie J, Mauer M, et al. Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group. JAMA Oncol. 2018;1;4(7):1003-1006. https://doi.org/10.1001/jamaoncol.2018.1080</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Davidson M, Wagner AD, Kouvelakis K, et al. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. Eur J Cancer. 2019;121: 40-47. https://doi.org/10.1016/j.ejca.2019.08.010</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175. https://doi.org/10.1200/JCO.1992.10.7.1171</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;15:1491-1498. https://doi.org/10.1200/JCO.2002.20.6.1491</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol. 2010;10:4086-4093. https://doi.org/10.1200/JCO.2009.27.0579</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-fluorouracil Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138. https://doi.org/10.1200/JCO.2006.10.4182</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165-1171. https://doi.org/10.1002/cncr.20878</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Yamada Y, Koizumi W, Nishikawa K, et al. Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. Cancer Sci. 2019;110(9):2875-2883. https://doi.org/10.1111/cas.14117</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Ros-Montana FJ, Navarro V, Comas C, et al. Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib. Ann Oncol. 2022;33(7): S136-S196. https://doi.org/10.1016/j.annonc.2022.07.512</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Wallis CJD, Butaney M, Satkunasivam R, et al. Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5(4):529-536. https://doi.org/10.1001/jamaoncol.2018.5904</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19(6):737-746. https://doi.org/10.1016/S1470-2045(18)30261-4</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Ye Y, Jing Y, Li L, et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 2020;11(1):1779. https://doi.org/10.1038/s41467-020-15679-x</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Unger JM, Vaidya R, Albain KS, et al. Sex Differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol. 2022;40(13):1474-1486. https://doi.org/10.1200/JCO.21.02377</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Duma N, Abdel-Ghani A, Yadav S, et al. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? The Oncologist. 2019;24(11):e1148-e1155. https://doi.org/10.1634/theoncologist.2019-0094</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine. 2018;16:94-94. https://doi.org/10.1186/s12967-018-1467-x</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Jing Y, Zhang Y, Wang J, et al. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. JNCI. 2021;113(10):1396-1404. https://doi.org/10.1093/jnci/djab035</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Owen DH, Wei L, Bertino EM, et al. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer. Clinical Lung Cancer. 2018;19(6):e893-e900. https://doi.org/10.1016/j.cllc.2018.08.008</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Wilcox NS, Rotz SJ, Mullen M, et al. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. Circ Res. 2022;130(4):632-651. https://doi.org/10.1161/CIRCRESAHA.121.319901</mixed-citation></ref></ref-list></back></article>
